oa Ketamine Metabolites-waiting in the Wings as Therapeutic Candidate for Depression?

References

1. MarwahaS. PalmerE. SuppesT. ConsE. YoungA.H. UpthegroveR. Novel and emerging treatments for major depression.Lancet20234011037114115310.1016/S0140‑6736(22)02080‑336535295
   [Google Scholar]
2. DalyE.J. SinghJ.B. FedgchinM. CooperK. LimP. SheltonR.C. ThaseM.E. WinokurA. Van NuetenL. ManjiH. DrevetsW.C. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression.JAMA Psychiatry201875213914810.1001/jamapsychiatry.2017.373929282469
   [Google Scholar]
3. DalyE.J. TrivediM.H. JanikA. LiH. ZhangY. LiX. LaneR. LimP. DucaA.R. HoughD. ThaseM.E. ZajeckaJ. WinokurA. DivackaI. FagioliniA. CubalaW.J. BitterI. BlierP. SheltonR.C. MoleroP. ManjiH. DrevetsW.C. SinghJ.B. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression.JAMA Psychiatry201976989390310.1001/jamapsychiatry.2019.118931166571
   [Google Scholar]
4. JohnstonJ.N. HenterI.D. ZarateC.A.Jr The antidepressant actions of ketamine and its enantiomers.Pharmacol. Ther.202324610843110.1016/j.pharmthera.2023.10843137146727
   [Google Scholar]
5. ZanosP. MoaddelR. MorrisP.J. GeorgiouP. FischellJ. ElmerG.I. AlkondonM. YuanP. PributH.J. SinghN.S. DossouK.S.S. FangY. HuangX.P. MayoC.L. WainerI.W. AlbuquerqueE.X. ThompsonS.M. ThomasC.J. ZarateC.A.Jr GouldT.D. NMDAR inhibition-independent antidepressant actions of ketamine metabolites.Nature2016533760448148610.1038/nature1799827144355
   [Google Scholar]
6. LiY. DuY. WangC. LuG. SunH. KongY. WangW. LianB. LiC. WangL. ZhangX. SunL. (2R,6R)-hydroxynorketamine acts through GluA1-induced synaptic plasticity to alleviate PTSD-like effects in rat models.Neurobiol. Stress20222110050310.1016/j.ynstr.2022.10050336532380
   [Google Scholar]
7. YeL. XiaoX. XuY. ZhengC. ChenS. LuoT. LiZ. DuY. YuanY. LiL. LiuB. QinW. ChouD. Prelimbic cortex miR-34a contributes to (2R,6R)-hydroxynorketamine-mediated antidepressant-relevant actions.Neuropharmacology202220810898410.1016/j.neuropharm.2022.10898435131296
   [Google Scholar]
8. PengW.H. KanH.W. HoY.C. Periaqueductal gray is required for controlling chronic stress-induced depression-like behavior.Biochem. Biophys. Res. Commun.2022593283410.1016/j.bbrc.2022.01.02535051779
   [Google Scholar]
9. XiongZ. FujitaY. ZhangK. PuY. ChangL. MaM. ChenJ. HashimotoK. Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model.Behav. Brain Res.201936811190410.1016/j.bbr.2019.11190430980851
   [Google Scholar]
10. YamaguchiJ. TokiH. QuY. YangC. KoikeH. HashimotoK. Mizuno-YasuhiraA. ChakiS. (2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice.Int. J. Neuropsychopharmacol.20184391900190710.1038/s41386‑018‑0084‑y29802366
    [Google Scholar]
11. ZhangK. FujitaY. HashimotoK. Lack of metabolism in (R)-ketamine’s antidepressant actions in a chronic social defeat stress model.Sci. Rep.201881400710.1038/s41598‑018‑22449‑929507385
    [Google Scholar]
12. ChouD. Brain-derived neurotrophic factor in the ventrolateral periaqueductal gray contributes to (2R,6R)-hydroxynorketamine-mediated actions.Int. J. Neuropharmacol.202017010806810.1016/j.neuropharm.2020.10806832222405
    [Google Scholar]